physician

  • Cardiology
    • Park, Jinny
      Park, Jinny

      Medical department

      Internal medicine

      Detailed specialty

      Hematology/Oncology

      position

      Professor

    • Detailed specialty

      Hematopoietic stem cell Transplantation
      Acute Leukemia (AML, ALL)
      Cronic Leukemia (CML, CLL)
      MDS (Myelo Dysplastic Syndrome)
      Lymphoma (HD, NHD)
      Aplastic Anemia
      Other Malignant Hematologic Disease
      Other Benign Hematologic Disease --ITP, Anemia etc.

    • Brief History

      Educational 2001~ 2003 Ph.D., Biochemistry
      Postgraduate School, Chonbuk National University,
      Chonju, Korea
      (Subject: Role of tumor suppressor, PTEN, in
      replicative cellular senescence)


      1998-2000 Master of Science, Internal Medicine
      Postgraduate School, Ulsan University, Seoul, Korea
      (Subject:The anti-lymphoma effect of simultaneous
      intraperitoneal injection of dendritic cells
      and lethally irradiated lymphoma cells in the
      murine lymphoma model)

      1986-1992 M.D.
      College of Medicine,
      Chonbuk National University, Chonju, Korea

      1984 -1986 Pre-Medicine
      College of Natural Sciences,
      Chonbuk National University, Chonju, Korea

      Career 2012~ Present Professor
      Division of Hematology/Oncology,
      Department of Medicine,
      Gachon University , Gil Hospital, Incheon, Korea

      2010 ~ 2011 Bone Marrow Transplant Visiting Investigator
      City of Hope National Medical Center,Duarte,
      California, U.S.A.

      2006-2012 Associate Professor
      Division of Hematology/Oncology,
      Department of Medicine,
      Gachon University , Gil Hospital, Incheon, Korea

      2004-2006 Assistant Professor
      Division of Hematology/Oncology,
      Department of Medicine,
      Cheju National University, School of Medicine
      Jeju, Korea

      2002 -2004 Clinical Instructor
      Hematology/Oncology, Samsung Medical Center,
      Seoul, Korea

      2000-2001 Clinical Research Physician , Oncoloogy Division
      Eli Lily Korea Seoul, Korea

      1998-2000 Clinical & Research Fellowship,
      Hematology/Oncology,Asan Medical Center,
      Seoul, Korea

      1994-1998 Residency, Internal Medicine
      Asan Medical Center, Seoul, Korea

      1992-1993 Internship
      Asan Medical Center, Seoul, Korea

      Training Certificate 2000, Diploma, Hematology/oncology, Korean Board of
      Internal Medicine
      1998, Diploma, Korean Board of Internal Medicine
      1992, Korean Medical License

    • Major Activities

      1. Huh J, Kim HJ, Jung CW, Kim HJ, Kim SH, Kim YK, Kim HJ,Shin MG, Moon JH, Sohn SK, Kim SH, Lee WS, Won JH, Moon YC, Kim H, Park J, Min WS, Kim DH. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia. Am J Hematol. 2012 Jun 8. doi: 10.1002/ajh.23281. [Epub ahead of print]
      2. Hong J, Park S, Park J*, Jang SJ, Ahn HK, Sym SJ, Cho EK, Shin DB, Lee JH. CD99 expression and newly diagnosed diffuse large B-cell lymphoma treated with rituximab-CHOP immunochemotherapy. Ann Hematol. 2012 Aug 3. [Epup ahead of print]e
      3. Sym SJ, Hong J, Jung M, Park J, Cho EK, Lee WK, Chung Min, Kim HS, , Lee JH, Shin DB. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 70(2):277-284, 2012
      4. Kim JE, Yoon DH, Jang G, Lee DH, Kim S, Park CS, Huh J, Kim WS, Park J, Lee JH, Lee SI, Suh C. A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas korean J Hematol 47(1) 53-59, 2012-04-18
      5. Hong J, Jung M, Kim YJ, Sym SJ, Kyung SY, Park J, Lee SP, Park JW, Cho EK, Jeong SH, Shin DB, Lee JH. Phase II study of combined belotecan and cisplatin as first-line chemotherapy in patients with extensive disease of small cell lung cancer. Cancer Chemother Pharmacol. 69 (1) 215-220, 2012
      6. Yi JH, Huh Jw, Kim H-J, Kim S-H, Kim H-J, Kim Y-K, Sohn S K, Moon JH, Kim SH, Kim KH, Won JH, Moon YC, Kim H, Park J, Jung CW, Kim DH(Dennis). Adverse prognostic impact of abnormal lesions detected by genome-wide single-nucleotide polymorphism-array based karyotyping analysis in acute myeloid leukemia with normal karyotype. JCO 29(35): 4702-4708, 2011
      7. Noh EM, Cho DH, Lee YR, Jeong YJ, Kim JH, Chae HS, Park J, Jung WS, Park SJ, Kim JS. Dimethylsulfoxide (DMSO) induces downregulation of heme oxygenase-1 (HO-1) in HL-60 cells: involvement of HO-1 in HL-60 cell differentiation. BMB Rep. 44(11):753-757,2011
      8. Hong J, Lee Y, Park Y, Kim SG, Hwang KH, Park SH, Jeong J, Kim KH, Ahn JY, Park S, Park J, Lee JH. Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol. 91(5) 687-695
      9. Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, Lee SR, Lee GW, Kim HJ, Kim HY, Oh SY, Kim HC, Eom HS, Chung J, Park J, Suh C, Ryoo BY. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 91(4) 543-551, 2011
      10. Kim AD, Kang KA, Zhang R, Lim CM, Kim HS, Kim DH, Jeon YJ, Lee CH, Park J, Chang WY, Hyun JW. Ginseng saponin metabolite induces apoptosis in MCF-7 breast cancer cells through the modulation of AMP-activated protein kinase. Environ Toxicol Pharmacol. Sep;30(2):134-140, 2010
      11. Hong J, Park S, Park J*, Kim HS, Kim KH, Ahn JY, Rim MY, Jung M, Sym SJ, Cho EK, Shin DB, Lee JH. Evaluation of prognostic values of clinical and histopathologic characteristics in diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy. Leuk Lymphoma. 52(10):1904-1912, 2011
      12. Lee JH, Jang JH, Park J, Park S, Joo YD, Kim YK, Kim HG, Choi CW, Kim SH, Park SK, Park E, Min YH. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome. Haematologica. 96(10):1441-1447, 2011
      13. Sohn SK, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma. 52(6):1024-1029, 2011
      14. Lee SP, Park S, Park J, Hong J, Ko YH. Clinicopathologic characteristics of CD99-positive diffuse large B-cell lymphoma. Acta Haematol.;125(3):167-174,
      15. Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang IG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 10;117(6):1958-1965, 2011
      16. Kim SJ, Oh SY, Kim JS, Kim H, Lee GW, Won JH, Shin HJ, Yang DH, Choi CW, Park J, Kim WS, Suh C. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma. Ann Hematol. 90(5):539-546, 2011
      17. Kim YS, Park SH, Kyung SY, Sym SJ, Lee SP, Park JW, Jung SH, Park J, Cho EK, Lee JH, Shin DB. Irinotecan plus carboplatin in patients with extensive-disease small-cell lung cancer. Med Oncol. 28(1):342-350. 2011
      18. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Lee WS, Suh C, Kim HJ. Multiple mucosa-associated lymphoid tissue organs involving marginal zone B cell lymphoma: organ-specific relationships and the prognostic factors. Consortium for improving survival of lymphoma study. Int J Hematol. 510-517, 2010
      19. Oh SY, Kim WS, Kim JS, Kim SJ, Lee S, Lee DH, Won JH, Hwang IG, Kim MK, Lee SI, Chae YS, Yang DH, Kang HJ, Choi CW, Park J, Kim HJ, Kwon JH, Lee HS, Lee GW, Eom HS, Kwak JY, Suh C, Kim HJ. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study. Cancer Sci. 101(11):2443-2447, 2010
      20. Hong J, Kim AJ, Park JS, Lee SH, Lee KC, Park J*, Sym SJ, Cho EK, Shin DB, Lee JH. Additional rituximab-CHOP (R-CHOP) versus involved-field radiotherapy after a brief course of R-CHOP in limited, non-bulky diffuse large B-cell lymphoma: a retrospective analysis. Korean J Hematol. 45(4):253-259,2010
      21. Park YM, Park J*, Jo Y, Kim S-H, Shin K-C, Won IS, Sym SJ, Cho EK, Shin DB, Lee JH. Prolonged Extreme Thrombocytosis in a Postsplenectomy Patient with Hereditary Spherocytosis. Korean J Hematol 44 (4) 298-303, 2009
      22. Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH, And The Korean Multiple Myeloma Working Party (Kmmwp). Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safty. Ann Hematol. 89(9) 905-912, 2010.
      23. Yi HS, Sym SJ, Park J∗,Cho EK, Shin DB, Lee JH. Typhlitis due to mucormycosis after chemotherapy in a patient with acute myeloid leukemia. Leuk Res. 34(7) e173-5, 2010
      24. Oh SY, Kim WS, Kim JS, Kim SJ, , Kwon HC, Lee DH, Won J H , Hwang IG , Kim M K , Lee SI , Chae YS, Yang D-H , Lee G-W , Choi CW , Park J , Suh C , Kim H-J. Pulmonary marginal zone B-cell lymphoma of MALTtype—What is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) Study. Ann Hematol. 89(6):563-568, 2010.
      25. Hong J, Kyung SY, Lee SP, Park JW, Jung SH, Lee JI, Park SH, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer. Korean J Intern Med 25(3):294-300, 2010.
      26. Yi HS, Sym SJ, Park J, Cho EK, Ha SY, Shin DB, Lee JH. Recurrent and metastatic trichilemmal carcinoma of the skin over the thigh: a case report. Cancer Res Treat. 42(3):176-9, 2010
      27. Kim YS, Hong J, Sym SJ, Park SH, Park J, Cho EK, Lee JH, Shin DB. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) combination chemotherapy as a salvage treatment in advanced gastric cancer. Cancer Res Treat. 42(1):24-29. 2010
      28. Park YM, Kim MK, , Won IS, Kim Y, Kyung SY,•Lee SP, LeeJI, Park JW, Jeong SH, Sym SJ, Park J, Cho EK, Shin DB, Lee JH. Clinical characteristics of lung cancer diagnosed from 2006 to 2008: Data from Gachon University Gil Hospital. Korean J Med 78:215-221, 2010
      29. Park YM, Park J*, Jo Y, Kim S-H, Shin K-C, Won IS, Sym SJ, Cho EK, Shin DB, Lee JH. Prolonged Extreme Thrombocytosis in a Postsplenectomy Patient with Hereditary Spherocytosis. Korean J Hematol 44 (4) 298-303, 2009
      30. Chung WK, Lee BK, Lee Y-R, Park J, Kwon HC. Diallyl Disulfide (DADS) Induces Upregulation of PTEN in Human Leukemia Cells. J Fd Hyg Safety 24 ( 1): 38~45, 2009
      31. Park S-H, Seo Y-H, , Park P-H, Ahn J-Y, Song Y-H, Kim J-E, Park J, Kim K-H. A Case of Primary Autoimmune Myelofibrosis. Korean J Hematol 44:157-162, 2009
      32. Oh SY, Kim WS, Kim JS, Kim SJ, , Kim SH, Lee DH, Won J H , Hwang IG , Kim M K , Lee SI , Kim JG, Yang D-H , Kang HJ, Choi CW , Park J, Choi YJ,Kim HJ, Kwon JH, Suh C , Kim H-J. Relapsed or refractory nongastric marginal zone B-cell lymphoma: Multicenter retrospective analysis of 92 cases. Am. J. Hematol. 84:826–829, 2009.
      33. Park SH, Ha SY, Lee JI, Lee H, Sim H, Kim YS, Hong J, Park J, Cho EK, Shin DB, Lee JH. Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung. J Korean Med Sci; 24: 448-52, 2009
      34. Park SH, Cho EK, Kim Y, Kyung SY, An CH ,Lee SP, Park JW, Jeong SH, Lee JI,• Choi SJ, Park J, Shin DB, Lee JH. Salvage treatment with topotecan in patients with irinotecan-refractory small cell lung cancer. Cancer Chemother Pharmacol 62:1009–1014, 2008
      35. Bang S-M, Ahn JY,Park J, Park SH, Park J, Cho EK, Shin DB, Lee JH
      Yoo SJ, Jeon IS,Kim Y-K, Kim H J,Kim H-N, Lee I-K,Kang HJ, Shin HY, Ahn HS Low Frequency and Variability of FLT3 Mutations in Korean Patients with Acute Myeloid Leukemia. J Korean Med Sci 23: 833-837, 2008
      36. Park SH, Hong J, Kim YS, Kim Y, Kyung SY,• An CH ,Lee SP, Park JW, Jeong SH, Park J, Cho EK, Shin DB, Lee JH. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer. Lung Cancer 62;72—77, 2008
      37. Yu HN, Lee YR, Noh EM, Lee KS, Song EK, Han MK, Lee YC, Yim C-Y, Park J, Kim BS, Lee SH, Lee SJ, Kim JS. Tumor necrosis factor-alpha enhances DMSO-induced differentiation of HL-60 cells through the activation of ERK/MAPK pathway. Int J Hematol 87:189–194, 2008
      38. Park SH, Kim YS, Hong J, Park J, Nam E, Cho EK, Shin DB, Lee JH, Lee WK, Chung M. Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study Anticancer Drugs 9(3):303-7, 2008
      39. Park SH, Cho MS, Kim YS, Hong J, Nam E, Park J, Cho EK, Shin DB, Lee JH, Lee WK.Self-reported health-related quality of life predicts survival for patients with advanced gastric cancer treated with first-line chemotherapy. Qual Life Res 17(2):207-214, 2008
      40. Park SH, Nam E, , Park J, Cho EK, Shin DB, Lee JH, Lee WK, Chung M,Lee SI.
      Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Ann Oncol. 19(4):729-733, 2008
      41. Lee KC, Lee SH, Lee Y, Park SH, Park J, Cho EK, Shin DB, Lee JH, Kim DY, Kim ST. Prospective Pilot Study of Consolidation Chemotherapy with Docetaxel and Cisplatin After Concurrent Chemoradiotherapy for Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 71(1):187-191, 2008
      42. Oh SY, Kwon HC, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, AhnYC, Oh SJ, Lee SI, Bang SM, Kim JH, Park J, Ryoo B-Y, Lee S-S, Kim HY, Park K, Kim H-J. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Letters 258 90–97, 2007
      43. Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 82(6):446-452, 2007
      44. Lee YR, Yu HN, Noh EM, Kim JS, Song EK, Han MK, Kim BS, Lee SH, Park J*. Peroxisome proliferator-activated receptor (PPAR) and retinoid acid receptor (RAR) synergistically upregulate the tumor suppressor PTEN in human promyeloid leukemia cells. Int J Hematol 85:231-237, 2007
      45. Lee J, Suh C, Park YH, Ko YH., Bang SM, Lee JH, Lee DH, Huh J, Oh SY, Kwon HC, Kim HJ, Lee SI, Kim J H, Park J, Oh SJ, Kim K, Jung CW, Park K, and Kim WS. Extranodal natural killer T-cell lymphoma, nasal-type: A prognostic model from a retrospective multicenter study. J Clin Oncol 24:612-618, 2006
      46. Park J, Kang KA, Zhang R, Piao MJ, Park S. Kim JS, Kang SS and Hyun JW. Antioxidant and cytotoxicity effects of luteolin. Journal of Toxicology and Public Health 22 (4): 391-395, 2006
      47. Park J, Kang KA, Zhang R, Piao MJ, Park S. Park JS, Kim YK, Rho MC, Lee HS and Hyun JW Antioxidant activity of water extract from the cultured mycelia of Phellinus baumii. Cancer Prevention Research 11(4): 325-335, 2006
      48. Kang KA, Zhang R, Piao MJ, Park S, Park J, Kim JS, Kang SS and Hyun JW. Screening of Antioxidant and anticancer effect from flavonoids. Cancer Prevention Research 11(3): 227-235, 2006
      49. Lee YR, Park J, Yu HN , Kim JS , Youn HJ, Jung S. Up-regulation of PI3K/Akt signaling by 17 -estradiol throughactivation of estrogen receptor-, but not estrogen receptor-, and stimulates cell growth in breast cancer cell Biochem. Biophys. Res. Commun. 336(4): 1221-1226, 2005
      50. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K.Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13(5): 859-864, 2005
      51. Lee YR, Shim HJ, Yu HN, Song EK, Park J, Kwon KB, Park JW, Rho HW, Park BH, Han MK, Kim JS. Dimethylsulfoxide induces upregulation of tumor suppressor protein PTEN through nuclear factor-kappaB activation in HL-60 cells. Leuk Res 29(4): 401-405, 2005
      52. Lee J, Lee MH , Park KW, Kang JH, Im DH, Kim K, Lee S-H, Kim WS, Park J, Jung CW, Park K. Influential Factors for the Collection of Peripheral Blood Stem Cells and Engraftment in Acute Myeloid Leukemia Patients in First Complete Remission. Int J Hematol 81(3):258-263, 2005
      53. Kim HY, Lee MH, Kim JH, Lee SH, Park J, Kim K, Park QE, Kim WS, Jung CW and Park K. Significance of multidrug resistance (MDR) activity in remission induction & survival of acute myeloid leukemia. Kor J Hematol 39(4):209-216, 2004
      54. Park SH, Kang WK, Lee HR, Park J, Lee K-E, Lee S-H, Park JO, Kim K, Kim WS, Chung CW, Im Y-H, Lee MH, Park CH, Park K. Docetaxel plus Cisplatin as Second-Line Therapy in Metastatic or Recurrent Advanced Gastric Cancer Progressing on 5-Fluorouracil based Regimen. Am J Clin Oncol 27(5):477-480, 2004
      55. Kim JH,Lee SH, Park J, Kim HY, Lee SI, Nam EM, Park JO, Kim K, Jung CW, Park YS, Im Y-H, Kang WK, Lee MH, and Park K. Extra-pulmonary Small-Cell Carcinoma: A single-institution experience. Jpn J Clin Oncol 34(5):250-254,2004
      56. Lee SH, Lee J, Park J, Park SH, Lee KE, Lee SI, Nam E, Park JO, Kim K, Jung CW, Park YS, Yoon SS, Kang WK, Lee MH, Park K, Im YH. Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Med Oncol 21(3): 223-231,2004
      57. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim JH, Kim HY, Park SH,, Lee K-E, Park JO, Kim K, Jung CW, Park YS, Im Y-H, Kang WK, Lee MH, and Park K. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small-cell lung cancer. Clin Cancer Res 10: 4383-4388, 2004
      58. Lee SH, Kang WK, Park J, Kim JH, Kim HY, Lee SI, Kim HYLee SI, Park JO, Kim K Jung CW, Park YS, Im Y-H, Lee MH and Park K. Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer. Br J Cancer 91(1):18-22, 2004
      59. Kim JH, Lee SH, Park J, Kim HY, Lee SI, Park JO, Kim K, Kim WS, Jung CW, Park YS, Im YH, Kang WK, Lee MH, Park K, Han JH, Ko YH. Primary Pulmonary Non-Hodgkin's Lymphoma. Jpn J Clin Oncol 34(9):510-514, 2004
      60. Lee J , Lee MH, Kim WS, Kim K, Park SH, Lee S-H, Lee K-E, Park J, Park JO, Chung CW, Im Y-H, Kang WK, Park K. Tuberculosis in hematopoietic stem cell transplantat recipients in korea. Int J Hematol 79(2):185-188, 2004
      61. Park SH, Lee MH, Lee SH, Lee KE, Park J, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K, Kim SW, Lee KH, Lee JH. The outcomes of hypertransfusion in major ABO Incompatible allogeneic stem cell transplantation. J Korean Med Sci. 19(1):79-82, 2004
      62. Lee S-H, Ahn YC, Kim HJ, Lim DH, Lee SI, Nam EM, Park SH, Park J, Lee K-E, Park JO, Kim K, Kim WS, Jung CW, Im Y-H, Kang WK, Lee MH, Park K. Early concurrent chemoradiotherapy with prolonged oral etoposide and cisplatin for limited-stage small-cell lung cancer. Jpn J Clin Oncol 33(12): 620-625, 2004
      63. Park J, Lee MH, Lee HR, Park SH, Lee SH, Lee K-E, Lee H, Park JO, Kim K, Jung CW, Im Y-H, Kang WK, Ko Y-H, and Park K. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia . Bone Marrow Transplant 32: 889-895,2003
      64. Park J, Ahn YC, Kim H, Lee S-H, Park SH, Lee K-E, Lim DH, Park JO, Kim K,Jung CW, Im Y-H, Kang WK, Lee MH, Park K: A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers. Lung Cancer 42: 227-235, 2003
      65. Park J, Suh C, Yang J, Park JS, Park KU, Min YJ, Kim HJ, Kim Y-H, Kim S-H. Active Immunization Using Dendritic Cells Mixed With Tumor Cells Inhibits The Growth Of Lymphomas. J Korean Med Sci 18: 372-380, 2003
      66. Park KU, Kim SH, Suh C, Kim S, Lee SJ, Park JS, Cho HJ, Kim KW, Lee K, Kim HJ, Park J, Min YJ, Kim TW, Lee JW, Kim SB, Kim SW, Lee KH,Lee JS. Correlation of Hematopoietic progenitor cell count determined by the SE-9000TM automated hematology analyzer with CD34+ cell count by flow cytometry in leukapheresis products. Ame J Hematol 67:42-47,2001
      67. Kim DY, Ko YJ, Park J . Hyperadhesiveness of pulmonary endothelial cells toward neutrophils by Vibrio vulnificus cytolysin. Chonbuk Univ Med J 25(2):21-32, 2001
      68.
      69. Kim HJ, Suh C, Kim SH, Kim SW , Kim SB, Kim KW, Cho HJ, Min YJ, Park J, Kim Ahm, Lee IS, Lee PR, Chi HS , Seo JJ, Kang W, Lee JS, Kim WK. Optimal umbilical cord blood processing : Basic study for the establishment of cord blood bank. Kor J Hematopoietic Stem Cell Transplant 5(1):61-68, 2000
      70. Min YJ, Kim SW, Suh C, Park J, Kim HJ, Kim JK, Kim TW, Lee JH, Kim SB, Lee KH, Lee JS, Kim WK, Kim SH. The possible cost effectiveness of peripheral blood stem cell mobilization with cyclophosphamide and the late addition of G-CSF. J Kor Med Sci 15:49-52, 2000
      71. Kim HJ, Suh C, Kim SH, Kim SW , Kim SB, Kim KW, Cho HJ, Min YJ, Park J, Kim Ahm, Lee IS, Lee PR, Chi HS , Seo JJ, Kang W, Lee JS, Kim WK: Optimal umbilical cord blood processing : Basic study for the establishment of cord blood bank. Kor J Hematopoietic Stem Cell Transplant 5(1):61-68, 2000
      72. Park JB, Suh C, Kim SH, Lee KN, Song HH, Park SS, Kim HJ, Min YJ, Park J, Choi SJ, Kim JK, Kim TW, Zang DY, Lee JH, Kim SB, Kim SW, Lee KH, Lee JS, Kim WK : Conventional treatments in patients with hodgkin,s disease. J Cancer Assoc 31(4): 821-829, 1999
      73. Shin ES, Myung SJ, Kim MH, Kim HK, Choe JW, Park J, Lee SK, Seo DW, Kim YS, Min YI : A case of adenosquamous carcinoma of the pancreas with unusual pancreatographic findings. Kor Soc Gastrointest Endosc 18(1): 91-95, 1998
      74. Bae CH, Kim WK, Par W, Park J, Kim JK, Choi SJ, Lee JH, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Koh Y, Sung KB, Kim SH : Prospective Study on Success and Complication Rate of Central Venous Catheterization in a University-affiliated Hospital. Kor J Med 55(2):195-201, 1998
      75. Park J, Suh C, Kim WK, Lee MS, Bae CH, Min YJ, Choi SJ, Kim TW, Zang DY, Lee JH, Kim SB, Kim SW, Lee KH, Chi HS, Lee JS, Kim SH : Leukopenia and neutropenia in healthy oreans. Kor J Med 54(3):397-405, 1998
      76. Zang DY, Lee JS, Kim TW, Jung BH, Yun HJ, Choi JS, Park J, Kim SB, Kim SW, Suh C, Lee KH, Kim WK, Kim SH : Clinical Courses and Prognostic Factors in Small Cell Lung Cancer. Kor J Med 54(1):90-100, 1998
      77. Kim HJ, Bae CH, Park J, Kim TW, Kim JT, Kim WK.: A case of HELLP syndrome and eclampsia associated with antiphospholipid syndrome Korean J of thrombosis and hemotasis. 4(1) 73-78, 1997
      78. Min YJ, Suh C, Lee JH, Chae YR, Kim S, Bae CW, Park J, Choi SJ, Kim TW, Yoon WJ, Jung BH, Zang DY, Choi JS, Kim SB, Kim SW, Lee KH, Lee JS, Kim WK, Ahn SH, Park JM, Kim SH : High-Dose Chemotherapy of Cyclophosphamide, Thiotepa, and Carboplatin(CTCb) with Autologous Peripheral Blood Stem Cell Transplantation for Hihg-Risk Primary Breast Cancer and Metastatic Breast Cancer. Kor J Med 53(4):482-487, 1997
      79. Park J, Lee JH, Kim TW, Yoon WJ, Chung BH, Zang DY, Kim SB, Kim SW, Suh C, Lee KH, Lee JS, Kim WK, Kim SH : Thalidomide Treatment for Extensive Chronic Graft-versus-Host Disease : A Case Report. Kor J Hematopoietic Stem Cell Transplant 1(2):99-104, 1997
      80. Choi SJ, Lee JH, Suh C, Youm NM, Chae YR, Kim S, Min YJ, Park J, Zang DY, Choi JS, Kim SB, Kim SW, Lee KH, Lee JS, Kim WK, Kim SH : Hematologic Recovery after Peripheral Blood Stem Cell Transplantation. Kor J Hematol 31(2):235-245, 1996


      Published Abstracts
      (International meeting)
      1. Park J, Noh EM, Lee Y-R, Lee E-K, Hong J, Lee JH, Kim J-S. Metalloporyphyrin controls the differentiation of human promyelocytic leukemic cells Poster presentation at the 2011 BMT Tandem Meetings in Honolulu, Hawaii
      2. Park J, Park SH, Kim SY, Ko YH, Kim K, Jung CW, Lee JH, Kang WK, Lee MH. Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia – Long - term F/U data. Biology of blood and marrow ransplantation , 16 (2S) ,S207 , (suppl; abstr 17007): Poster presentation at the 2010 BMT Tandem Meetings in Orlando, FL. USA, 24-28, Feb , 2010
      3. Park J, Sym SJ, Cho EK, Shin DB, Lee JH, Kim JS. Heme oxygenase-1 plays an important role in DMSO-induced differentiation of HL-60 cells.
      - Poster presentation at the 47th Annual Meeting of the Japan Society of
      . Clinical Oncology in Yokohama, Japan , 22 - 24 Oct. 2009
      4. Park Y, Sym S, Park J, Cho E, Shin D, Lee J. A randomized phase II study of irinotecan monotherapy versus irinotecan plus 5fluorouracil/leucovorin combination as a salvage chemotherapy in previously treated patients with advanced/metastatic gastric cancer. Eur J Cancer 7 (2S)| 383, 2009
      - Poster presentation at the Joint ECCO 15 - 34TH ESMO
      Multidisciplinary Congress, BERLIN, 20 - 24 Sep. 2009
      5. Ryoo BY, Suh C, Kim WS, Kim JS, Lee JJ, Yang DH, Kang HJ,Kim SJ, Lee SR, Lee GW, Kim HJ, Kim HY, Oh SY, Kim H, . Eom HS, Chung J, Park J, Park YM, Park JS. Rituximab plus cvp (cyclophosphamide, vincristine, and prednisolone) combination chemotherapy in advanced stage marginal zone b-cell lymphoma as a first-line therapy
      - Poster presentation at the 14TH Congress of the European Hematology Association Berlin, Germany, 4-7 June, 2009
      6. Sym S, Park S, Park J, , Kwon K, Jung I, Cho E, Lee W, Chung M, Shin D, Lee J. A randomized phase II trial of weekly docetaxel plus either cisplatin or oxaliplatin in patients with previously untreated advanced gastric cancer: Preliminary results. J Clin Oncol 27(15s), 2009 (suppl; abstr 4566)
      -Poster presentation at the 2009 ASCO Annual Meeting, 2009
      7. Kim J, Kim W, Suh C, Yang D, Eom H, O S, Bang S, Lee S, Kim H, Park J, Won J, Yoon S, Kim C. The role of radiotherapy, performance status,and dosage of methotrexate according to theagein primary cns lymphoma patients received upfront high dose methotrexate based chemotherapy -- Poster presentation at the 10th International Conference On Malignant Lymphoma, Lugano, Switzerland, June 04-07, 2008
      8. Chung WK, Lee YR, Noh EM, Han MK, Song EK, Lee KS, , Lee YC, Yim C-Y, Kwon HC Park J*, Kim JS. Diallyl disulfide (DADS) enhances all -trans- retinoic acid (ATRA)-induced differentiation of human leukemia cells. AACR Meeting Abstracts 2008 (suppl; abstr 1279) –
      Poster presentation at the 99th AACR Annual Meeting, San Diego, CA, Apr 12-16, 2008
      9. Kim J, Kim W, Suh C, Yang D, Eom H, O S, Bang S, Lee S, Kim H, Park J, Won J, Yoon S, Kim C. The role of radiotherapy, performance status,and dosage of methotrexate according to theagein primary cns lymphoma patients received upfront high dose methotrexate based chemotherapy ---- Poster presentation at the 10th International Conference On Malignant Lymphoma, Lugano, Switzerland, June 04-07,, 2008
      10. Park S, Lee S, Park J, Cho E, Shin D, Lee J. Phase II study of oral S-1 in pretreated patients with recurrent or metastatic head and neck cancer. J Clin Onco 26 (15S), 2008 (suppl; abstr 17007)
      11. Park SH, Kim YS, Hong J, Park J, Cho EK, Shin DB, Lee JH, Lee SI. Opioid rotation versus combination for cancer patients with chronic uncontrolled pain: a randomized study. Eur J Cancer 5 (4S)| 156, 2007
      -Poster presentation at the 2007 ESMO Conference Lugano (ECLU)
      12. Kim YS, Hong J, Park SH, Park J, Cho EK, Shin DB, Lee JH. A pilot study of topotecan in patients with irinotecan-refractory small cell lung cancer.
      Eur J Cancer 5 (4S)| 388, 2007
      - Poster presentation at the 2007 ESMO Conference Lugano (ECLU)
      13. Park S, Park J, Cho E, Shin D. Second-line therapy with irinotecan or gefitinib in docetaxel pretreated patients with non-small cell lung cancer: A new treatment strategy according to clinical predictors for response. J Clin Onco 25 (18S), 2007 (suppl; abstr 18026)
      14. Noh EM, Lee YR, Kim JS., Han MK, Park SH, Shin DB, Lee JH, Park J. TNF-a sensitizes HL-60 cells to DMSO-induced differentiation. AACR Meeting Abstracts 2007(suppl; abstr 4386)
      - Poster presentation at the 98th AACR Annual Meeting, Los Angeles, CA
      14-18 Apr, 2007
      15. J. Park, Y. Lee, H. Yu, M. Han, B. Kim and J. Kim. PPARr agonist, troglitazone induce growth arrest and apoptosis in MDA-MB-231 human breast cancer cell. J Clin Onco, 24 (18S ), 2006 (suppl; abstr 13155)
      16. Park J, Yu HN, Lee YR, Shim H-J, Han MK, Song EK, Kim JS. Tumor Necrosis Factor – enhances human leukemia cell differentiation induced by DMSO, but not retinoic acid. AACR-NCI-EORTC International Conference Molecular Targets and Cancer Therapeutics , 2005 (suppl; 227)- Poster presentation at the 2005 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Philadelphia, PA 14 - 18 Nov, 2005
      17. Kim ST, Park JO, Park J, Han JH, Kim J G, Shim YM, Park YS, Ahn YC, Kim H, Im Y-H, Kang WK, Park K. Clinical and histologic correlation of thymic epithelial tumors (TETs) in Korea. J Clin Onco 23 (16S), 2005 (suppl; abstr 7278)
      18. Oh SY, Ryoo BY, Kim WS, Park YH, Kim K, Kim HJ, Kwon JM, Lee J, Ko YH, Ahn YC, Oh SJ, Lee SI, Kim HJ, Kwon HC, Bang SM, Kim JH, Park J, Lee SS, Kim HY, Park K. Nongastric Marginal Zone B-Cell Lymphoma: Analysis of 247 Cases - Clinical Presentation and Treatment Outcomes of Nongastric Marginal Zone B-Cell Lymphoma. Blood 106 (11),2005(suppl; abstr 1491)
      -poster presentation at the 47th American Society of Hematology meeting
      19. Park J, Lee MH, Lee SH, Park JO, Kim K, Jung CW, Kim WS, Park YS, Im Y-H, Kang WK, Park K. Predictive Value of Cytogenetics on Outcomes of Stem Cell Transplantation in Acute Myeloid Leukemia. Blood 104 (11), 2004(suppl; abstr 4397)
      20. Park J, Lee YR, Shim HJ, Kwak J-Y, Yim C-Y Song EK,Han MK, , Park JW, Rho HW, LeeSY Kim JS. All Trans-Retinoic Acid (ATRA) in Combination with PPAR-g Ligand Synergistically Enhances Inhibition of Cell Growth and Induction of Tumor Suppressor PTEN in Leukemic Cells. Blood 104 (11), 2004 (suppl; abstr 4328)
      21. Park Keun W, Lee J, Park J, Kim H Y, Lee MH, Lee SH, Kang JH., Kim K, Jung CW, , Kim WS, Park JO, Im Y-H, Park YS, Kang WK, Park K. A Randomized Trial of Short-Course Preemptive Ganciclovir Compared with Conventional Ganciclovir Therapy To Prevent Cytomegalovirus Blood 104 (11), 2004 (suppl; abstr 3162)
      -poster presentation at the 46th American Society of Hematology meeting
      22. Lee SH, Lee J, , Im Y-H, Park J, Kim H Y, Park YS, Kim JH, Nam SJ, Yang JH, Park K. Doxorubicin plus docetaxel as neoadjuvant treatment in patients with large (T>5cm), locally advanced carcinoma of the breast. J Clin Onco 22 (14S), 2004 (suppl; abstr 746)
      23. Park J, Lee Y–R, Shim H-J, Rho H-W, Park J-W, Song E- K, Han M-K, Jhee E-C, Lee MH and Kim J-S. Control of Tumor Suppressor Protein PTEN by Dimethlysulfoxide in HL-60 Cells J Clin Onco 22 (14S), 2004 (suppl; abstr 3156)
      24. Lee H, Kim EJ, Yu JJ, Shu SW, Ko YH, Baek SY, Park J, Park K, Lee MH. Anti-tumor effect and immuno-toxicity of target-specific drug delivery system : Doxorubicin-encapsulated nano particle.
      - Poster presentation at the 95th Annual Meeting of American Association of Cancer Research, 2004
      25. Park J, Lee Y–R, Shim H-J, Hur H, Han M-K, Song E- K, Park J-W, Rho H-W, Jhee E-C, Lee MH and Kim J-S. Combination of cigluatazone, a pharmacological PPAR- ligand, with retinoic acid synergistically enhances upregulation of novel tumor suppressor PTEN in HL-60 cells. Blood 102:442b,2003
      - poster presentation at the 45th American Society of Hematology meeting)
      26. Park J, Ahn YC, Kim H, Lee S-H, Park SH, Lee K-E, Lim DH, Park JO, Kim K, Jung CW, Im Y-H, Kang WK, Lee MH, Park K: A phase II trial of concurrent chemoradiation therapy followed by consolidation chemotherapy with oral etoposide and cisplatin for locally advanced inoperable non-small cell lung cancers
      – Poster presentation at the 10th World Conference on Lung Cancer , 2003
      - Oral presentation at the 6th Internatinal Conference of The Asian Clinical Oncology Society, 2003
      27. Park J, Park BB, Kim JY, Lee SH, Lee SI, Kim JH, Kim HY, Park SH, , Lee K-E, Park JO, Kim K, Jung CW, Park YS, Im Y-H, Kang WK, Lee MH, and Park K. Gefitinib (Iressa, ZD 1839) mono therapy as a salvage regimen for previously treated advanced non-small-cell lung cancer.
      –Poster presentation at the 10th World Conference on Lung Cancer , 2003 &
      - Oral presentation at the 6th International Conference of The Asian Clinical Oncology Society, 2003
      28. Park J, Kim SH, Yang JH, Suh C, Min YJ, Kim TW, Kim SB, Kim SW, Lee JS, Kim WK; Active immunization using dendritic cells mixed with tumor cells inhibits the growth of Lymphoma Blood 94(10 suppl.1):93a,1999
      -poster presentation at the 41th American Society of Hematology meeting

[Last updated at 2017.05.17]